Astex Pharma and Otsuka’s Cancer Trial Meets Primary Endpoints

Astex Pharma and Otsuka’s Cancer Trial Meets Primary Endpoints

Source: 
BioSpace
snippet: 

Astex Pharmaceuticals, which is a member of the Otsuka group, and Otsuka Pharmaceutical announced that their ASCERTAIN Phase III clinical trial of cedazuridine and decitabine (ASTX727) compared to decitabine IV alone hit its primary endpoints. The fixed-dose combination was being evaluated in adults with intermediate and high-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).